Filing Flows

Filing Flows › Evolent Health (EVH) › Stock forecast & fair value

Evolent Health (EVH) stock forecast and fair value

Evolent Health (EVH) trades at $4.58. 12 analysts' median price target is $6.00 (+31%), from $3.00 to $8.00. Across 15 valuation methods the middle fair value is $21.38 (+367%).

Price$4.58
Median target$6.00
Fair value, middle$21.38
EPS beat rate60%
Evolent Health fair value by method (price $4.58)Evolent Health fair value by method (price $4.58)low – highpoint estimateEV/Sales vs peers$23.34EV/Sales vs peers, weighted$24.26Residual income−$2.89Analysts' price targets$5.83Shareholder yield (dividends + buyb…$7.61Path-to-margin DCF$33.69Path-to-margin DCF, dilution-adjust…$23.12Exit-multiple (venture) method$21.35EV/Sales vs Rule of 40 (all-company…$29.37Survival-weighted value$11.29

Fair value by method

MethodLowPointHighvs price
EV/Sales vs peers$13.22$23.34$31.74+410%
EV/Sales vs peers, weighted$17.79$24.26$35.43+430%
Residual income−$2.85−$2.89−$2.94-163%
Analysts' price targets$3.00$5.83$8.00+27%
Shareholder yield (dividends + buybacks)$6.29$7.61$9.63+66%
Path-to-margin DCF$6.56$33.69$60.75+636%
Path-to-margin DCF, dilution-adjusted$3.80$23.12$47.07+405%
Exit-multiple (venture) method$13.61$21.35$29.77+366%
EV/Sales vs Rule of 40 (all-company fit)$6.09$29.37$93.23+541%
Survival-weighted value$1.85$11.29$22.99+147%

Evolent Health's latest quarter

Evolent Health, Q3 2026: revenue $725M (+51% year over year), operating margin -0.9%, net loss $23.6M, operating cash flow $26.4M. The chart follows the revenue to costs, profit and cash.

Questions

What is the price target for EVH stock?

The median of 12 analysts' 12-month targets is $6.00, +31% from $4.58; the range is $3.00 to $8.00. The average rating is buy.

What is Evolent Health's fair value?

The fair-value methods on Filing Flows (DCF, Monte Carlo, peer multiples and others) put it between −$2.89 and $33.69, with a middle value of $21.38 against a price of $4.58. Each method's assumptions are on the page.

Does Evolent Health usually beat earnings estimates?

It beat the consensus EPS estimate in 60% of the quarters on record.

Is EVH stock a buy?

Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.